MiRNA与血小板活性的研究进展：一个新的评估抗血小板治疗效果的潜在生物标志物

摘要/Abstract

摘要：

微RNA（microRNA，miRNA）是一种非编码的小RNA分子，在人体内含量丰富且参与许多生命活动的调控。MiRNA在血小板形成、mRNA调控、蛋白合成及激活各个过程均有特异性表达，如 miRNA参与调节巨核细胞的生成、分化和血小板激活通路等。许多研究试图进一步阐明miRNA与血小板活性的关系，为寻找评估抗血小板治疗效果的生物标志物提供了新的方向。

文章导读： 与现有评估抗血小板治疗效果的方法相比，微RNA具有潜在的更好的临床应用价值。

关键词: 微RNA; 血小板; 生物标志物

Abstract:

MicroRNA (miRNA) is a non-coding small RNA molecule, participating in regulating biologic activities, with a large quantity. MiRNAs have their specific expression in different processes related to platelet formation, mRNA regulation, protein synthesis and platelet activation. For instance, miRNA participates in regulating the biogenesis and differentiation of megakaryocytes and the pathway of platelet activation. Scientists pay a lot of efforts to figure out the relationship between miRNA and platelet reactivity, which points out a new possibility to evaluate the efficacy of anti-platelet therapy by using miRNA as a novel biomarker. This article is trying to review the studies about the relevance between miRNA and platelet reactivity.

Key words: MicroRNA; Platelet; Biomaker

林泽明1，2，刘新通2. MiRNA与血小板活性的研究进展：一个新的评估抗血小板治疗效果的潜在生物标志物[J]. 中国卒中杂志, 2015, 10(04): 331-335.

LIN Ze-Ming, LIU Xin-Tong.. Advances in Correlation between miRNA and Platelet Activity:a Novel and Potential Biomarker to Evaluate the Efficacy of Anti-platelet Therapy[J]. Chinese Journal of Stroke, 2015, 10(04): 331-335.

参考文献

1 Lee RC, Feinbaum RL, Ambros V, et al. The C.

elegans heterochronic gene lin-4 encodes small RNAs

with antisense complementarity to lin-14[J]. Cell,

1993, 75:843-854.

2 Bar tel DP. MicroRNAs:target recognition and

regulatory functions[J]. Cell, 2009, 136:215-233.

3 Mraz M, Pospisilova S. MicroRNAs in chronic

lymphocytic leukemia:From causality to associations

and back[J]. Expert Rev Hematol, 2012, 5:579-581.

4 Sepramaniam S, Tan JR, Tan KS, et al. Circulating

microRNAs as biomarkers of acute stroke[J]. Int J

Mol Sci, 2014, 15:1418-1432.

5 Hulsmans M, Holvoet P. MicroRNA-containing

microvesicles regulating inflammation in association

with atherosclerotic disease[J]. Cardiovasc Res, 2013,

100:7-18.

6 Landry P, Plante I, Ouellet DL, et al. Existence of

a microRNA pathway in anucleate platelets[J]. Nat

Struct Mol Biol, 2009, 16:961-966.

7 Michelson AD. How platelets work:platelet function and

dysfunction[J]. J Thromb Thrombolysis, 2003, 16:7-12.

8 Osman A, Falker K. Characterization of human

platelet microRNA by quantitative PCR coupled with

an annotation network for predicted target genes[J].

Platelets, 2011, 22:433-441.

9 Hunter MP, Ismail N, Zhang X, et al. Detection of

microRNA expression in human peripheral blood

microvesicles[J]. PLoS One, 2008, 3:e3694.

10 Chen X, Ba Y, Ma L, et al. Characterization of

microRNAs in serum:a novel class of biomarkers for

diagnosis of cancer and other diseases[J]. Cell Res,

2008, 18:997-1006.

11 Georgantas RW 3rd, Hildreth R, Morisot S, et al.

CD34+ hematopoietic stem-progenitor cell microRNA

expression and f unct ion:a ci rcuit diagram of

differentiation control[J]. Proc Natl Acad Sci USA,

2007, 104:2750-2755.

12 Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated

control of cell fate in megakaryocyte-erythrocyte

progenitors[J]. Dev Cell, 2008, 14:843-853.

13 Girardot M, Pecquet C, Boukour S, et al. miR-28

is a thrombopoietin receptor targeting microRNA

detected in a fraction of myeloproliferative neoplasm

patient platelets[J]. Blood, 2010, 116:437-445.

14 Starczynowski DT, Kuchenbauer F, Argiropoulos

B, et al. Identification of miR-145 and miR-146a as

mediators of the 5q- syndrome phenotype[J]. Nat Med,

2010, 16:49-58.

15 Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA

fingerprints during human megakaryocytopoiesis[J].

Proc Natl Acad Sci U S A, 2006, 103:5078-5083.

16 Edel s t e i n LC, McKen z ie SE, Shaw C, e t a l .

MicroRNAs in platelet production and activation[J]. J

Thromb Haemost, 2013, 11:340-350.

17 Kondkar AA, Bray MS, Leal SM, et al. VAMP8/

endobrevin is overexpressed in hyperreactive human

platelets:suggested role for platelet microRNA[J]. J

Thromb Haemost, 2010, 8:369-378.

18 Nagalla S, Shaw C, Kong X, et al. Platelet microRNAmRNA

coexpression profiles correlate with platelet

reactivity[J]. Blood, 2011, 117:5189-5197.

19 Gidlöf O, van der Brug M, Ohman J, et al. Platelets

activated during myocardial infarction release

functional miRNA, which can be taken up by

endothelial cells and regulate ICAM1 expression[J].

Blood, 2013, 121:3908-3917, S1-S26.

20 Shi R, Ge L, Zhou X, et al. Decreased platelet miR-

223 expression is associated with high on-clopidogrel

platelet reactivity[J]. Thromb Res, 2013, 131:508-513.

21 Edelstein LC, Simon LM, Montoya RT, et al. Racial

difference in human platelet PAR4 reactivity reflects

expression of PCTP and miR-376c[J]. Nat Med, 2013,

19:1609-1616.

22 Aradi D, Storey RF, Komócsi A, et al. Expert position

paper on the role of platelet function testing in patients

undergoing percutaneous coronary intervention[J].

Eur Heart J, 2014, 35:209-215.

23 Voora D1, Ginsburg GS, Akerblom A. Platelet RNA

as a novel biomarker for the response to antiplatelet

therapy[J]. Future Cardiol, 2014, 10:9-12.

24 Willeit P, Zampetaki A, Dudek K, et al. Circulating

mic roRNAs a s novel bioma rke r s for plat elet

activation[J]. Circ Res, 2013, 112:595-600.

25 Stratz C, Nührenberg TG, Binder H, et al. Micro-array

profiling exhibits remarkable intra-individual stability

of human platelet micro-RNA[J]. Thromb Haemost,

2012, 107:634-641.

[1]	孟一然, 王卫. 椎动脉残端综合征致后循环反复梗死1例并文献复习[J]. 中国卒中杂志, 2022, 17(12): 1381-1384.
[2]	张亮, 黄立安, 徐安定. CHANCE 2开创了基因指导下卒中抗血小板治疗的先河[J]. 中国卒中杂志, 2022, 17(08): 807-812.
[3]	孔晓彤, 刘佩芳, 蔡涵璐, 王宇, 王丽华. 基于快速CYP2C19基因检测的快代谢型急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 814-816.
[4]	冯博, 赵彩君, 常立国. 基于快速CYP2C19基因检测发现携带功能缺失等位基因的急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 817-820.
[5]	中国卒中学会神经介入分会. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J]. 中国卒中杂志, 2022, 17(08): 863-888.
[6]	李振华, 刘著, 胡全忠. 非致残性缺血性脑血管事件药物治疗进展[J]. 中国卒中杂志, 2022, 17(04): 407-412.
[7]	刘忠, 刘媛媛, 徐少峰, 郭伟, 康海. 系统免疫炎性指数与急性缺血性卒中严重程度及预后的相关性分析[J]. 中国卒中杂志, 2022, 17(03): 285-291.
[8]	王拥军, 熊云云, 李子孝, 张玉梅, 杨晓萌, 王上, 霍晓川, 杨明, 谢雪微, 罗岗, 陈晓霖, 李光硕, 王利圆, 王传颖, 闫然, 王文洁, 段春苗, 路正钊. 卒中：回眸2021[J]. 中国卒中杂志, 2022, 17(01): 1-20.
[9]	张俊良, 黄双凤, 徐璐瑶, 向薇, 张曼曼, 梁志刚. 替罗非班治疗MRI筛选的轻中度非心源性缺血性卒中的安全性和有效性研究[J]. 中国卒中杂志, 2022, 17(01): 66-72.
[10]	赵义. 困局与破局：聚焦大动脉炎并发脑梗死[J]. 中国卒中杂志, 2021, 16(12): 1199-1202.
[11]	王聪杰, 李虹, 郑丽, 刘珊, 卢海丽, 陈娜, 张斌, 周衡. 轻型缺血性卒中静脉溶栓后双重抗血小板疗效观察[J]. 中国卒中杂志, 2021, 16(10): 1044-1049.
[12]	张凤, 武希庆, 冯乐燕, 贾玉勤. 双侧延髓内侧梗死病例报道2例及文献复习[J]. 中国卒中杂志, 2021, 16(10): 1062-1066.
[13]	程越, 邵腾飞, 黄丽丽, 杨丹, 徐运. 血小板功能实验预测氯吡格雷用于缺血性卒中二级预防的有效性和安全性分析[J]. 中国卒中杂志, 2021, 16(06): 574-580.
[14]	王璐瑶, 熊云云, 王上. 负荷剂量双联抗血小板治疗后超时间窗无影像错配的急性缺血性卒中患者阿替普酶静脉溶栓1例报告[J]. 中国卒中杂志, 2021, 16(06): 616-618.
[15]	于一娇，刘丽，杜娟，李薇，林甜，路冬煦，蔡艺灵. 内囊预警综合征的临床特征和预后[J]. 中国卒中杂志, 2020, 15(12): 1317-1321.